Cargando…
Risk stratification in cardiogenic shock: a focus on the available evidence
Cardiogenic shock is a clinical syndrome which is defined as the presence of primary cardiac disorder that results in hypotension together with signs of organ hypoperfusion in the state of normovolaemia or hypervolaemia. It represents a complex life-threatening condition, characterized by a high mor...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197897/ https://www.ncbi.nlm.nih.gov/pubmed/34263413 http://dx.doi.org/10.1007/s10741-021-10140-7 |
_version_ | 1784727514756677632 |
---|---|
author | Sciaccaluga, C. Mandoli, G. E. Ghionzoli, N. Anselmi, F. Dini, C. Sorini Righini, F. Cesareo, F. D’Ascenzi, F. Focardi, M. Valente, S. Cameli, M. |
author_facet | Sciaccaluga, C. Mandoli, G. E. Ghionzoli, N. Anselmi, F. Dini, C. Sorini Righini, F. Cesareo, F. D’Ascenzi, F. Focardi, M. Valente, S. Cameli, M. |
author_sort | Sciaccaluga, C. |
collection | PubMed |
description | Cardiogenic shock is a clinical syndrome which is defined as the presence of primary cardiac disorder that results in hypotension together with signs of organ hypoperfusion in the state of normovolaemia or hypervolaemia. It represents a complex life-threatening condition, characterized by a high mortality rate, that requires urgent diagnostic assessment as well as treatment; therefore, it is of paramount important to advocate for a thorough risk stratification. In fact, the early identification of patients that could benefit the most from more aggressive and invasive approaches could facilitate a more efficient resource allocation. This review attempts to critically analyse the current evidence on prognosis in cardiogenic shock, focusing in particular on clinical, laboratoristic and echocardiographic prognostic parameters. Furthermore, it focuses also on the available prognostic scores, highlighting the strengths and the possible pitfalls. Finally, it provides insights into future direction that could be followed in order to ameliorate risk stratification in this delicate subset of patients. |
format | Online Article Text |
id | pubmed-9197897 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-91978972022-06-16 Risk stratification in cardiogenic shock: a focus on the available evidence Sciaccaluga, C. Mandoli, G. E. Ghionzoli, N. Anselmi, F. Dini, C. Sorini Righini, F. Cesareo, F. D’Ascenzi, F. Focardi, M. Valente, S. Cameli, M. Heart Fail Rev Article Cardiogenic shock is a clinical syndrome which is defined as the presence of primary cardiac disorder that results in hypotension together with signs of organ hypoperfusion in the state of normovolaemia or hypervolaemia. It represents a complex life-threatening condition, characterized by a high mortality rate, that requires urgent diagnostic assessment as well as treatment; therefore, it is of paramount important to advocate for a thorough risk stratification. In fact, the early identification of patients that could benefit the most from more aggressive and invasive approaches could facilitate a more efficient resource allocation. This review attempts to critically analyse the current evidence on prognosis in cardiogenic shock, focusing in particular on clinical, laboratoristic and echocardiographic prognostic parameters. Furthermore, it focuses also on the available prognostic scores, highlighting the strengths and the possible pitfalls. Finally, it provides insights into future direction that could be followed in order to ameliorate risk stratification in this delicate subset of patients. Springer US 2021-07-14 2022 /pmc/articles/PMC9197897/ /pubmed/34263413 http://dx.doi.org/10.1007/s10741-021-10140-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Sciaccaluga, C. Mandoli, G. E. Ghionzoli, N. Anselmi, F. Dini, C. Sorini Righini, F. Cesareo, F. D’Ascenzi, F. Focardi, M. Valente, S. Cameli, M. Risk stratification in cardiogenic shock: a focus on the available evidence |
title | Risk stratification in cardiogenic shock: a focus on the available evidence |
title_full | Risk stratification in cardiogenic shock: a focus on the available evidence |
title_fullStr | Risk stratification in cardiogenic shock: a focus on the available evidence |
title_full_unstemmed | Risk stratification in cardiogenic shock: a focus on the available evidence |
title_short | Risk stratification in cardiogenic shock: a focus on the available evidence |
title_sort | risk stratification in cardiogenic shock: a focus on the available evidence |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197897/ https://www.ncbi.nlm.nih.gov/pubmed/34263413 http://dx.doi.org/10.1007/s10741-021-10140-7 |
work_keys_str_mv | AT sciaccalugac riskstratificationincardiogenicshockafocusontheavailableevidence AT mandolige riskstratificationincardiogenicshockafocusontheavailableevidence AT ghionzolin riskstratificationincardiogenicshockafocusontheavailableevidence AT anselmif riskstratificationincardiogenicshockafocusontheavailableevidence AT dinicsorini riskstratificationincardiogenicshockafocusontheavailableevidence AT righinif riskstratificationincardiogenicshockafocusontheavailableevidence AT cesareof riskstratificationincardiogenicshockafocusontheavailableevidence AT dascenzif riskstratificationincardiogenicshockafocusontheavailableevidence AT focardim riskstratificationincardiogenicshockafocusontheavailableevidence AT valentes riskstratificationincardiogenicshockafocusontheavailableevidence AT camelim riskstratificationincardiogenicshockafocusontheavailableevidence |